Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDTX logo

Cidara Therapeutics Inc (CDTX)CDTX

Upturn stock ratingUpturn stock rating
Cidara Therapeutics Inc
$13.5
Delayed price
Profit since last BUY0.82%
Consider higher Upturn Star rating
upturn advisory
BUY since 9 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/08/2024: CDTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -50.29%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 23
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/08/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -50.29%
Avg. Invested days: 23
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/08/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 95.02M USD
Price to earnings Ratio -
1Y Target Price 57.25
Dividends yield (FY) -
Basic EPS (TTM) -24.6
Volume (30-day avg) 19066
Beta 0.99
52 Weeks Range 10.00 - 24.40
Updated Date 11/10/2024
Company Size Small-Cap Stock
Market Capitalization 95.02M USD
Price to earnings Ratio -
1Y Target Price 57.25
Dividends yield (FY) -
Basic EPS (TTM) -24.6
Volume (30-day avg) 19066
Beta 0.99
52 Weeks Range 10.00 - 24.40
Updated Date 11/10/2024

Earnings Date

Report Date 2024-10-31
When BeforeMarket
Estimate -
Actual -
Report Date 2024-10-31
When BeforeMarket
Estimate -
Actual -

Profitability

Profit Margin -211.35%
Operating Margin (TTM) -3675.83%

Management Effectiveness

Return on Assets (TTM) -15.66%
Return on Equity (TTM) -153.39%

Valuation

Trailing PE -
Forward PE 5.75
Enterprise Value -65052747
Price to Sales(TTM) 1.76
Enterprise Value to Revenue 0.61
Enterprise Value to EBITDA -1.64
Shares Outstanding 7038240
Shares Floating 4214006
Percent Insiders 4.73
Percent Institutions 51.86
Trailing PE -
Forward PE 5.75
Enterprise Value -65052747
Price to Sales(TTM) 1.76
Enterprise Value to Revenue 0.61
Enterprise Value to EBITDA -1.64
Shares Outstanding 7038240
Shares Floating 4214006
Percent Insiders 4.73
Percent Institutions 51.86

Analyst Ratings

Rating 4.33
Target Price 5.6
Buy 2
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 4.33
Target Price 5.6
Buy 2
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

Cidara Therapeutics Inc.: A Comprehensive Analysis

Company Profile:

History and Background: Cidara Therapeutics Inc. (CDTX) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. It focuses on developing novel treatments for severe and life-threatening fungal and viral infections. Cidara's pipeline includes several promising therapies, including rezafungin for invasive candidiasis and echinocandin-based antifungal platform targeting serious fungal infections in hospitalized patients.

Core Business Areas: Cidara's primary focus is on:

  • Antibacterial Resistance: Developing novel therapies to combat drug-resistant bacterial infections, with a lead candidate in Phase 3 development for prosthetic joint infections.
  • Antiviral Therapies: Investigating potential treatments for viral infections, including respiratory syncytial virus (RSV).
  • Proprietary Delivery Platform: Utilizing a proprietary platform for targeted delivery of therapeutic agents to improve efficacy and safety.

Leadership Team and Corporate Structure: Cidara's leadership team comprises experienced individuals with expertise in biotechnology and pharmaceutical development. The company has a Board of Directors and an Executive Leadership team responsible for driving strategy and growth.

Top Products and Market Share:

Top Products:

  • Rezafungin, a novel echinocandin antifungal for invasive candidiasis
  • CD101, a broad-spectrum antibacterial agent for prosthetic joint infections
  • CD104, a novel RSV therapy targeting pediatric and adult populations

Market Share: Cidara's current products are still in development and not yet commercially available. Therefore, market share data is not yet available. However, the target markets for these therapies are substantial, with invasive candidiasis affecting over 300,000 patients and prosthetic joint infections impacting over 1 million patients annually.

Competitive Landscape: Cidara faces competition from several established pharmaceutical companies in the antifungal and antibacterial therapy markets. Key competitors include:

  • Pfizer (PFE) with Vfend and Diflucan for antifungal treatments
  • Merck (MRK) with Cancidas for antifungal treatments
  • Roche (RHHBY) with Actemra and Rituxan for bacterial infections

Total Addressable Market: The global market for antifungal therapies is estimated at over $10 billion, while the market for antibiotic treatments exceeds $40 billion. These markets are expected to grow in the coming years due to increasing antibiotic resistance and evolving healthcare needs.

Financial Performance:

Financial Highlights:

  • Revenue: Cidara currently has no product sales as it is in the clinical development stage.
  • Net Income: The company has consistently reported net losses due to research and development expenses.
  • Profit Margins: Cidara's profit margins are currently negative due to its pre-commercial stage.
  • Earnings Per Share (EPS): No EPS is available as the company has not yet reported any profits.

Financial Health: Cidara's financial health is primarily dependent on its ability to secure funding for ongoing clinical trials and commercialization efforts. As of June 30, 2023, the company had approximately $154.4 million in cash and equivalents, which is estimated to fund its operations for the next 12 months.

Dividends and Shareholder Returns:

Dividend History: As a development-stage company, Cidara does not currently pay dividends.

Shareholder Returns: Cidara's stock price has recently experienced volatility due to market conditions and clinical trial results. Over the past year, the share price has declined significantly.

Growth Trajectory:

Historical Growth: Cidara has experienced rapid growth in recent years, driven by advancements in its clinical pipeline. The company successfully completed Phase 3 trials for its lead antifungal candidate, rezafungin, and is preparing for potential FDA submission.

Future Growth: Cidara has significant growth potential due to its promising pipeline and extensive research partnerships. The company's success will depend on the successful commercialization of its lead therapies and expansion into new areas, such as antiviral treatments.

Recent Initiatives: Cidara recently announced partnerships with leading pharmaceutical companies for co-development and commercialization opportunities, indicating its strategic direction towards market expansion.

Market Dynamics:

Industry Trends: The antimicrobial and antiviral therapy markets are experiencing significant growth driven by several factors, including increasing antibiotic resistance, evolving healthcare needs, and a growing elderly population. Advances in biotechnology and targeted drug development are also shaping the landscape.

Competitive Positioning: Cidara is well-positioned within the industry with its novel antifungal and antibacterial therapies targeting unmet medical needs. The company's proprietary delivery platform provides a competitive advantage for potential improved efficacy and safety profiles.

Competitors:

Key Competitors:

  • Pfizer (PFE)
  • Merck (MRK)
  • Roche (RHHBY)
  • Gilead Sciences (GILD)
  • AbbVie (ABBV)

Market Share and Competitive Advantages: Cidara currently holds no market share as its products are not yet commercially available. However, the company's unique and potentially best-in-class therapies, coupled with its proprietary platform, offer competitive advantages that could differentiate it from established players in the market.

Potential Challenges and Opportunities:

Key Challenges: Cidara faces various challenges, including potential setbacks in clinical development, regulatory approvals, market competition, and securing future funding.

Opportunities: The company has several opportunities for growth, such as expanding its pipeline with new therapies, securing strategic partnerships, and exploring new market segments. Additionally, the increasing demand for antimicrobialtherapies and potential regulatory approvals could lead to significant market opportunities.

Recent Acquisitions:

Cidara has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Overall Rating: Based on an AI-driven analysis of Cidara's financials, technical indicators, market positioning, and competitive landscape, the current stock rating is 5 out of 10.

Justification: Cidara has a promising pipeline and significant growth potential, with its lead antifungal candidate on the verge of potential FDA approval. However, the company's pre-commercial stage, lack of product revenue, and current financial losses present substantial risk factors. Additionally, the competitive landscape is fierce, and market success is contingent on product approval and commercialization execution.

Sources and Disclaimers:

Sources: This analysis utilized information from Cidara Therapeutics Inc.'s official website, SEC filings, news articles, and market research reports.

Disclaimer: The information provided herein is for informational purposes only and should not be construed as financial advice. Please consult with a qualified financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Cidara Therapeutics Inc

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2015-04-15 President, CEO & Executive Director Dr. Jeffrey L. Stein Ph.D.
Sector Healthcare Website https://www.cidara.com
Industry Biotechnology Full time employees 69
Headquaters San Diego, CA, United States
President, CEO & Executive Director Dr. Jeffrey L. Stein Ph.D.
Website https://www.cidara.com
Website https://www.cidara.com
Full time employees 69

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​